Spots Global Cancer Trial Database for A Study of Ado-trastuzumab Emtansine (T-DM1)-Induced Peripheral Neuropathy in HER2-positive Breast Cancer Patients
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of Ado-trastuzumab Emtansine (T-DM1)-Induced Peripheral Neuropathy in HER2-positive Breast Cancer Patients
Official Title: A Study of the Natural History of Ado-trastuzumab Emtansine (T-DM1)-Induced Peripheral Neuropathy in HER2-positive Breast Cancer Patients
Study ID: NCT05889988
Conditions
Interventions
Study Description
Brief Summary: Researchers plan to study the natural history of ado-trastuzumab emtansine (T-DM1)-induced neuropathy both in patients without any history of neuropathy or previous neurotoxic agent use and in patients who have such a history.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Fairview Grand Itasca Clinic & Hospital, Grand Rapids, Minnesota, United States
Fairview Range Medical Center, Hibbing, Minnesota, United States
MMCORC CentraCare Monticello Cancer Center, Monticello, Minnesota, United States
Fairview Northland Medical Center, Princeton, Minnesota, United States
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Sanford Health Thief River Falls Clinic, Thief River Falls, Minnesota, United States
Sanford Health Worthington, Worthington, Minnesota, United States
Contact Details
Name: Charles L. Loprinzi, M.D.
Affiliation: Mayo Clinic in Rochester
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
